Literature DB >> 7567763

Polymyalgia rheumatica, temporal arteritis and malignancy.

C A Speed1, I Haslock.   

Abstract

The use of steroid therapy in polymyalgia rheumatica and temporal arteritis is necessary and usually effective, but may mask coexisting disease. The importance of early consideration of other disorders in such patients is illustrated by three case histories.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7567763      PMCID： PMC2398202          DOI： 10.1136/pgmj.71.838.500

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  12 in total

1.  Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis?

Authors:  G P Brittain; G G McIlwaine; J A Bell; J M Gibson
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

2.  Polymyalgia rheumatica.

Authors:  G G Hunder; T F Disney; L E Ward
Journal:  Mayo Clin Proc       Date:  1969-12       Impact factor: 7.616

3.  Malignancy in association with polymyalgia rheumatica and temporal arteritis.

Authors:  J von Knorring; T Somer
Journal:  Scand J Rheumatol       Date:  1974       Impact factor: 3.641

4.  Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Acta Med Scand       Date:  1981

5.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

Review 6.  Relation of giant cell arteritis to polymyalgia rheumatica.

Authors:  L A Healey
Journal:  Baillieres Clin Rheumatol       Date:  1991-12

Review 7.  Temporal arteritis without an elevated erythrocyte sedimentation rate. Case report and review of the literature.

Authors:  R L Wong; J H Korn
Journal:  Am J Med       Date:  1986-05       Impact factor: 4.965

8.  Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis.

Authors:  J R Park; J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

9.  The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome.

Authors:  M E Ellis; S Ralston
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

10.  Prognosis and management of polymyalgia rheumatica.

Authors:  J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103
View more
  3 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  Polymyalgia rheumatica, temporal arteritis and malignancy.

Authors:  E P Das-Gupta; P Bandyopadhyay; J L Shun; J P Ng
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 3.  The thromboembolic risk in giant cell arteritis: a critical review of the literature.

Authors:  A Guida; A Tufano; P Perna; P Moscato; M T De Donato; R Finelli; D Caputo; M N D Di Minno
Journal:  Int J Rheumatol       Date:  2014-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.